A pivotal study of Ad-RTS-hIL-12 + veledimex for recurrent glioblastoma multiforme (GBM)

Trial Profile

A pivotal study of Ad-RTS-hIL-12 + veledimex for recurrent glioblastoma multiforme (GBM)

Planning
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 12 Oct 2017 According to a ZIOPHARM Oncology media release, this trial is expected to begin by the end of 2017.
    • 20 Feb 2017 New trial record
    • 16 Feb 2017 According to a ZIOPHARM Oncology media release, the company plans to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top